Bonna Leerhøy1, Andreas Nordholm-Carstensen1, Srdan Novovic2, Mark Berner Hansen1,3, Lars Nannestad Jørgensen1. 1. a Digestive Disease Center, Bispebjerg Hospital , University of Copenhagen , Copenhagen , Denmark ; 2. b Department of Gastroenterology and Gastrointestinal Surgery , Hvidovre Hospital, University of Copenhagen , Copenhagen , Denmark ; 3. c AstraZeneca, Research and Development , Gothenburg , Sweden.
Abstract
OBJECTIVE: The aim of this study was to assess the influence of patient body weight on the clinical effect of 100 mg diclofenac administered as a single dose for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP). MATERIALS AND METHODS: All patients subjected to endoscopic retrograde cholangiopancreatography (ERCP) from 2009 to 2014 were evaluated for inclusion. In total, 772 patients were included of whom 378 (49%) received diclofenac prophylaxis. RESULTS: In the diclofenac prophylaxis group, body weight was higher in patients with PEP (mean ± SD: 82 ± 18 kg) than in patients without PEP (74 ± 18 kg) (p = 0.029). In patients not receiving prophylaxis, body weight was not associated with the occurrence of PEP (mean ± SD: 77 ± 18 vs 75 ± 18 kg, respectively, p = 0.450). In an adjusted analysis, higher patient body weight was inversely associated with the clinical effect of 100 mg diclofenac for the prophylaxis of PEP. CONCLUSIONS: High patient body weight was associated with a reduced effect of 100 mg diclofenac for prophylaxis of PEP.
OBJECTIVE: The aim of this study was to assess the influence of patient body weight on the clinical effect of 100 mg diclofenac administered as a single dose for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP). MATERIALS AND METHODS: All patients subjected to endoscopic retrograde cholangiopancreatography (ERCP) from 2009 to 2014 were evaluated for inclusion. In total, 772 patients were included of whom 378 (49%) received diclofenac prophylaxis. RESULTS: In the diclofenac prophylaxis group, body weight was higher in patients with PEP (mean ± SD: 82 ± 18 kg) than in patients without PEP (74 ± 18 kg) (p = 0.029). In patients not receiving prophylaxis, body weight was not associated with the occurrence of PEP (mean ± SD: 77 ± 18 vs 75 ± 18 kg, respectively, p = 0.450). In an adjusted analysis, higher patient body weight was inversely associated with the clinical effect of 100 mg diclofenac for the prophylaxis of PEP. CONCLUSIONS: High patient body weight was associated with a reduced effect of 100 mg diclofenac for prophylaxis of PEP.
Authors: Bonna Leerhøy; Daniel M Shabanzadeh; Andreas Nordholm-Carstensen; Srdan Novovic; Mark B Hansen; Lars N Jørgensen Journal: United European Gastroenterol J Date: 2017-11-09 Impact factor: 4.623
Authors: Juan Pablo Román Serrano; José Jukemura; Samuel Galante Romanini; Paúl Fernando Guamán Aguilar; Juliana Silveira Lima de Castro; Isabela Trindade Torres; José Andres Sanchez Pulla; Otavio Micelli Neto; Eloy Taglieri; José Celso Ardengh Journal: World J Gastrointest Endosc Date: 2020-11-16
Authors: Christina J Sperna Weiland; Xavier J N M Smeets; Robert C Verdonk; Alexander C Poen; Abha Bhalla; Niels G Venneman; Wietske Kievit; Hester C Timmerhuis; Devica S Umans; Jeanin E van Hooft; Marc G Besselink; Hjalmar C van Santvoort; Paul Fockens; Marco J Bruno; Joost P H Drenth; Erwin J M van Geenen Journal: Endosc Int Open Date: 2022-03-14